SCHEMBL5098757

SCHEMBL5098757

Cn1cncc1C(N)c1ccc(C#N)cc1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FNTA P49354 18/20 0.50
FNTB P49356 18/20 0.50
PGGT1B P53609 8/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5099434 0.82 FNTA (0.50) FNTAFNTBPGGT1B
SCHEMBL5088977 0.82 FNTA (0.50) FNTAFNTBPGGT1B
Hydrochloric Acid SCHEMBL7048952 0.81 FNTA (0.49) FNTAFNTBPGGT1B
Hydrochloric Acid SCHEMBL7570009 0.79 HPGDS (0.39) FNTAFNTBPGGT1B
SCHEMBL7567592 0.78 CYP11B1 (0.46) FNTAFNTBPGGT1B
SCHEMBL7183607 0.78 FNTA (0.47) FNTAFNTBPGGT1B
SCHEMBL7572062 0.74 CYP11B1 (0.47) FNTAFNTBPGGT1B
SCHEMBL7570561 0.73
SCHEMBL18228420 0.72 CFTR (0.44)
Hydrochloric Acid SCHEMBL7571150 0.72 FNTA (0.69) FNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323570-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2008-01-29 US disclosed
US-7211595-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2007-05-01 US disclosed
US-20060264476-A1 Farnesyltransferase Inhibitors ABBVIE INC. 2006-11-23 US disclosed
EP-1339695-B1 FARNESYLTRANSFERASE INHIBITORS ABBOTT LAB (US) 2006-04-19 EP disclosed
US-20030087940-A1 Farnesyltransferase inhibitors ABBVIE INC. 2003-05-08 US disclosed
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents ABBOTT LABORATORIES 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents FNTB, FNTA, ACAT2 FNTA 2/4885FNTB 1/4885PGGT1B 28/4885
US-20060264476-A1 Farnesyltransferase Inhibitors FNTB, FNTA, FDPS FNTA 2/4885FNTB 1/4885PGGT1B 16/4885
US-20030087940-A1 Farnesyltransferase inhibitors FNTB, FNTA, FDPS FNTA 2/4885FNTB 1/4885PGGT1B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.